Maridebart cafraglutide (previously known as AMG133) is a bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers
In the stomach, GLP-1s slow down gastric emptying, that is, they keep food in the stomach longer than normally occurs, thus giving you a sense of fullness (satiety) you may not have experienced before
Affected individuals may be asymptomatic, may have recurrent exertional dyspnea, chest pain or syncope
Omega-3 supplements can thin the blood and interact with those who take anticoagulants and antiplatelet medications, such as aspirin, clopidogrel, prasugrel, and warfarin
Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment